PA
OCUL icon

Parallel Advisors’s Ocular Therapeutix OCUL Stock Holding History

Parallel Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$9 – 3621
2024
Q4 		$9 Hold
1
– – ﹤0.01% 3505
2024
Q3 		$9 Buy
+1
New +$8 ﹤0.01% 3382
2022
Q1 		– Sell
-1,012
Closed -$7K – 3174
2021
Q4 		$7K Buy
+1,012
New +$7.86K ﹤0.01% 2268

Other funds holding OCUL

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors's OCUL Position: Q1 2025 in Review

Parallel Advisors sold out of Ocular Therapeutix (OCUL) in Q1 2025, closing a stake of 1 share — an estimated $9 sold.

Parallel Advisors first reported a position in OCUL in Q4 2021 and held it in 3 quarters. The position peaked at $7K in Q4 2021. 196 funds tracked by Wall St. Rank hold OCUL as of Q1 2025.

  • Parallel Advisors reported no remaining Ocular Therapeutix position as of Q1 2025 after selling out during the quarter.
  • Parallel Advisors sold 1 Ocular Therapeutix share in Q1 2025, an estimated $9.
  • Parallel Advisors first reported a position in Ocular Therapeutix in Q4 2021 and held it in 3 quarters.
  • Parallel Advisors's Ocular Therapeutix position peaked at $7K in Q4 2021.
  • 196 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2025.

Based on Parallel Advisors's 13F filing for Q1 2025, filed 8 Apr 2025.